Shares of CytRx Corp. (NASDAQ:CYTR) traded up 3.5% on Monday . The stock traded as high as $2.39 and last traded at $2.34, with a volume of 840,401 shares trading hands. The stock had previously closed at $2.26.

Several analysts have recently weighed in on the stock. FBR & Co reiterated an “outperform” rating and set a $8.00 target price on shares of CytRx Corp. in a research report on Tuesday, March 15th. Jefferies Group reiterated a “hold” rating on shares of CytRx Corp. in a research report on Wednesday, June 8th. Zacks Investment Research upgraded shares of CytRx Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of CytRx Corp. in a report on Saturday, April 23rd. Finally, Aegis lifted their price target on shares of CytRx Corp. from $9.00 to $12.00 and gave the company a “buy” rating in a report on Monday, March 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $7.50.

The firm has a 50-day moving average price of $2.47 and a 200 day moving average price of $2.53. The company’s market capitalization is $167.57 million.

CytRx Corp. (NASDAQ:CYTR) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.07. On average, analysts anticipate that CytRx Corp. will post ($0.78) EPS for the current year.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.